1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,300 | 3,340 | 11:46 | |
| 3,240 | 3,460 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Addex beschafft sich im Rahmen seines ATM-Vertrags 2,8 Millionen US-Dollar | 405 | Moneycab | Genf - Addex Therapeutics (SIX und Nasdaq: ADXN), ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung eines Portfolios neuartiger kleinmolekularer allosterischer... ► Artikel lesen | |
| Mi | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mi | Addex Therapeutics raises $2.8M via ATM offering, extending runway to Q4 2027 | 1 | Seeking Alpha | ||
| Mi | Addex nimmt mehrere Millionen US-Dollar über ATM-Vereinbarung ein | 6 | cash | ||
| Mi | Addex Therapeutics: ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027 | 380 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, August 26, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 08.07. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| ADDEX THERAPEUTICS SA ADR Aktie jetzt für 0€ handeln | |||||
| 08.07. | Addex Therapeutics: Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness | 488 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, July 8, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 30.06. | Addex Therapeutics: Addex Shareholders Approve All Resolutions at Annual General Meeting | 461 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 30, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 25.06. | Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript | 6 | Benzinga.com | ||
| 25.06. | Addex Therapeutics GAAP EPS of -CHF0.01 | 2 | Seeking Alpha | ||
| 25.06. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.06. | Addex fällt im ersten Quartal tiefer ins Minus | 447 | Moneycab | Genf - Das Biotechunternehmen Addex hat im ersten Quartal des Geschäftsjahres 2026 einen etwas grösseren Verlust geschrieben. Die liquiden Mittel beliefen sich auf 0,9 Millionen Franken, nachdem es... ► Artikel lesen | |
| 25.06. | Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 423 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 25, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 22.06. | Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026 | 412 | GlobeNewswire (Europe) | Geneva, Switzerland, June 22, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric... ► Artikel lesen | |
| 05.06. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 05.06. | Addex Therapeutics: Addex Convenes Annual General Meeting 2026 | 425 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 5, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 15.05. | Addex Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 20 | SEC Filings | ||
| 30.04. | Addex Therapeutics reports FY results | 22 | Seeking Alpha | ||
| 30.04. | Earnings Call Transkript: Addex Therapeutics H2 2026 offenbart strategische Neuausrichtung | 14 | Investing.com Deutsch | ||
| 30.04. | Addex Therapeutics Q4 2025 Earnings Call Transcript | 13 | Benzinga.com |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,454 | -0,12 % | Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid? | ||
| BAUSCH HEALTH | 5,483 | 0,00 % | Bausch Health Companies Inc.: Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board | LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 29,350 | 0,00 % | Assembly Biosciences: Vor diesem HSV-Moment zählt alles | ||
| BIONANO GENOMICS | 1,170 | 0,00 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| AMARIN | 12,000 | 0,00 % | Amarin Corporation plc: New REDUCE-IT Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients | ||
| ALTIMMUNE | 2,700 | +0,19 % | Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update | Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 7,100 | +1,43 % | Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 25,810 | +2,67 % | Acadia Pharmaceuticals Inc.: European Commission Approves DAYBU (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,985 | -0,82 % | Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock | ||
| ARTIVION | 22,800 | -2,56 % | Artivion, Inc.: Artivion Reports Second Quarter 2026 Financial Results | Second Quarter & Recent Business Highlights:
Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,868 | 0,00 % | Biodexa Pharmaceuticals PLC: Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP | August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa"... ► Artikel lesen | |
| AKANDA | 3,060 | 0,00 % | Akanda Corp: Akanda's First Towers & Fiber Increases Recurring Revenue with Completion of 200 KM Fiber Network | Toronto, Ontario--(Newsfile Corp. - August 13, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications... ► Artikel lesen | |
| ATYR PHARMA | 0,457 | -1,51 % | aTyr Pharma, Inc.: aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD | Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of approximately... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 5,165 | 0,00 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) | WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory... ► Artikel lesen | |
| AVALO THERAPEUTICS | 16,960 | +0,24 % | Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates | Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1ß... ► Artikel lesen |
ADDEX THERAPEUTICS SA ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 3,600 Euro und damit +7,14 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADDEX THERAPEUTICS SA ADR finden Sie auf Wallstreet Online.